
Headache and Migraine
Latest News
Latest Videos

CME Content
More News

A pair of neurologists from the University of California, Irvine, provided commentary on the ways to help young investigators find their footing in research settings, and exposing them to opportunities major governmental agencies can provide. [WATCH TIME: 4 minutes]

The general neurologist at Brigham and Women’s Hospital described the approach and mindset in teaching neurology as the field continuously evolves. [WATCH TIME: 3 minutes]

At the 2024 AUPN Annual Meeting, a pair of neurologists provided perspectives on the attributes and ethics that make a great educator, stressing passion, intellectual humility, and inclusivity, among others. [WATCH TIME: 5 minutes]

FDA Supports A-Synuclein Assay for PD Trials, VES001 Meets Primary End Point, Digital Migraine Therapeutic CT-132 Performs
Neurology News Network. for the week ending September 14, 2024. [WATCH TIME: 4 minutes]

Treatment with Lu AG09222 as a migraine preventive was safe, with common adverse events that included COVID-19, nasopharyngitis, and fatigue.

Across 4 trials with over 4800 patients, rimegepant demonstrated superior pain and symptom relief 2 hours post-dose, with fewer requiring rescue medication.

CT-132, a digital therapy, targets brain hypersensitivity and provided non-pharmacological treatment, showing promise for integration into migraine management.

Tolebrutinib Shows Promise in Non-Relapsing Secondary Progressive MS, Fenebrutinib Suppresses Relapses in New Data, FDA Accepts Resubmitted NDA for AXS-07
Neurology News Network. for the week ending September 7, 2024. [WATCH TIME: 4 minutes]

AXS-07 has been supported by data from 2 major phase 3 trials in which treatment with the agent led to significant reliefs in pain freedom, the most bothersome symptoms, and acute medication use.

The system is composed of the Neuroblade, a single-use multifunctional neuroendoscope; the Neuropad, a reusable medical-grade tablet; and Clearpath, a disposable transparent access sheath.

In a 3-month trial at two primary care sites, neurology referrals decreased by 77%, and brain MRI scans dropped by 35%.

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on chronic migraine.

AMX0035's Potential in Tauopathies, Alkermes Initiates Phase 2 Study of ALKS 2680, EryDex Falls Short in Phase 3 ATTeST Trial
Neurology News Network. for the week ending August 31, 2024. [WATCH TIME: 4 minutes]

A recent prospective study reveals significant alterations in heavy metal and trace element levels among patients with migraine, suggesting these imbalances may play a role in the pathogenesis and progression of the condition.

Medtronic DBS Approved for Asleep Surgery, BHV-2100 Shows Early Promise, AOC 1044 Continues Dystrophin Production in Latest Update
Neurology News Network. for the week ending August 17, 2024. [WATCH TIME: 4 minutes]

The study suggests that overall, migraine is not directly related to traditional CVRFs, and further research is needed, especially in younger populations, to explore these relationships over longer periods.

The chair of Allegheny Health Network’s Neurosciences Institute talked about its comprehensive center that integrates multidisciplinary resources and technology to provide quality care for patients with chronic neurologic conditions. [WATCH TIME: 5 minutes]

The drug showed a highly favorable pharmacokinetic profile, with maximal concentrations (Tmax) achieved within 1.5 to 2 hours and a mean terminal elimination half-life ranging between 8 to 12 hours.

IND Cleared for Cell Therapy in Progressive MS, FDA Approves IPX203, Migraine Treatment Nerivio Safe in Pediatric Populations
Neurology News Network. for the week ending August 10, 2024. [WATCH TIME: 4 minutes]

Neal K. Shah, CEO of CareYaya Health Technologies, explores the potential of AI-enhanced, neurotech-powered music therapy as a revolutionary solution to chronic pain management and the opioid crisis.

In pediatric patients, the average treatment intensity was 22.8% of the maximum stimulator intensity, with slightly lower intensity levels compared to previous studies in adolescents and adults.

The meeting with the American Neurologic Association fosters collaboration, networking, and joint sessions, enhancing knowledge sharing among academic neurologists.

Sleeping Around the Podcast × NeurologyLive brings you a clinical overview of the use of erenumab, an FDA-approved medication for migraine, and the interactions between CGRP and orexin.

In this episode, the panel discusses the emerging challenges for neurology departments, the shortage of neurologists, and the ways to disseminate between useful and useless information amid a busy career.

John England, MD, and Lisa Merlin, MD, commented on the significant changes to neurology over the years and how education aligns with the latest in treatments advancements and understanding of neurological disorders.






















